This page shows the latest trametinib news and features for those working in and with pharma, biotech and healthcare.
That included Servier’s leukaemia treatment Oncaspar(pegaspargase), which had five studies deemed to be at risk, while others included Novartis’ Mekinist(trametinib; three studies) and Pfizer’s Ibrance(palbociclib; two
Proactive adjuvant treatment could extend melanoma patient lives. England’s cost effectiveness watchdog NICE has recommended the use of Novartis’ Tafinlar (dabrafenib and Mekinst (trametinib) combination in melanoma. ... Clinical trial results showed
The EMA has approved Tafinlar (dabrafenib) and Mekinist (trametinib) for the adjuvant (post-surgery) treatment of stage III melanoma patients with BRAF V600 mutations, following in the footsteps of the US
The combination of Novartis BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) met its objective with a 53% reduction in death or disease recurrence in the COMBI-AD trial, which ... Both ipilimumab and the combination of
The European Commission has cleared BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) for patients with advanced or metastatic NSCLC whose tumours bear the BRAF V600 mutation.
CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung
More from news
Approximately 7 fully matching, plus 33 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...